HALOZYME THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $14.85B
- P/E (TTM)
- 36.1
- Dividend yield
- –
About Halozyme Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Halozyme Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes drug delivery platforms and specialized injection devices. The company's core offering is its ENHANZE technology, powered by the proprietary recombinant human hyaluronidase enzyme rHuPH20, which facilitates rapid subcutaneous delivery of injectable biologics and fluids to reduce patient treatment burden. Halozyme also develops the Hypercon and Surf Bio drug concentration technologies, alongside pressure-assisted auto-injectors and multi-dose pens. Its business model spans licensing proprietary delivery platforms to biopharmaceutical partners, collaborative drug-device product development, and the direct commercialization of proprietary offerings such as Hylenex recombinant and XYOSTED. Customers and collaborators include major global pharmaceutical companies, healthcare providers, and patients.
The company operates from its principal executive offices and research facilities situated in San Diego, California. Halozyme licenses and collaborates with international biopharmaceutical partners that market therapies and advance programs across multiple global markets, including the United States, Europe, Canada, Japan, and China.
Summary of the business section of Halozyme Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- HALOZYME THERAPEUTICS, INC.
- Founded
- 1998
- Headquarters
- San Diego, CA
- Address
- 12390 El Camino Real 92130
- Phone
- (858) 794-8889
- Website
- halozyme.com
- Employees
- 423, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst& Young LLP, San Diego, California
Stock & identifiers
- Ticker
- HALO
- Exchange
- Nasdaq
- IPO date
- Mar 16, 2004
- Shares outstanding
- 113M, Jul 31, 2026
- Public float
- $4.50B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1159036
- CUSIP
- 40637H109
- ISIN
- US40637H1095
- LEI
- 529900242I3SV9AGM753
- EIN
- 88-0488686
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Helen Torley | PRESIDENT AND CEO, Director | 787,780 |
| Darren Snellgrove | SVP, Chief Financial Officer | – |
| David A. Ramsay | EVP, PRESIDENT, DRUG DELIVERY | 10,000 |
| Mark Howard Snyder | SVP, CHIEF LEGAL OFFICER | 52,644 |
| Cortney Caudill | SVP, CHIEF OPERATING OFFICER | 15,912 |
| Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | 42,102 |
| Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 173,756 |
| Matthew L. Posard | Director | 58,839 |
| Dannielle Appelhans | Director | 1,161 |
| Bernadette Connaughton | Director | 40,418 |
| Mahesh Krishnan | Director | 14,462 |
| Jeffrey William Henderson | Director | 36,572 |
| Barbara Gayle Duncan | Director | 23,715 |
| James Paul Lang | Director | 4,685 |
| Akiko Moni Miyashita | Director | 24,937 |
| Connie Matsui | Director | 183,035 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Helen I Torley | $23.17M | $39.73M | $3.59M | $158 | $125 |
| FY2024 Helen I Torley | $12.74M | $20.75M | $4.22M | $112 | $93 |
| FY2023 Helen I Torley | $11.82M | -$3.61M | $3.57M | $87 | $94 |
| FY2022 Helen I Torley | $9.70M | $22.82M | $2.42M | $133 | $90 |
| FY2021 Helen I Torley | $7.45M | $5.99M | $2.40M | $94 | $100 |
| FY2020 Helen I Torley | $6.52M | $24.37M | $1.81M | $241 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of February 10, 2026, we had 423 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 24, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 26, 2022 | Tender offer | Third-party tender offer for the company's shares |
| Nov 2, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 20, 2007 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 9, 2007 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 9, 2007 | Delisting | Notice of delisting from exchange (Form 25) |
| Jun 29, 2006 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Oct 27, 2004 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 12, 2004 | Name change | Name changed from GLOBAL YACHT SERVICES INC to HALOZYME THERAPEUTICS INC |
| May 16, 2003 | Late filing | Notification of late filing |
| Aug 14, 2002 | Late filing | Notification of late filing |